Could the human body itself be the human body’s greatest weapon against crippling disease?

That’s the hope of regenerative medicine, a field in biotechnology that aims to harness the human body’s regenerative capabilities to treat a wide range of illnesses.

One of Australia’s biggest proponents of the research, Stem Cells Australia, says the goal of regenerative medicine is to develop new therapies and treatments “by either recruiting stem cells within organs to promote repair, or administering new cells and tissue made from stem cells to restore normal function after disease, illness or injury”.

What’s more, recent analysis from Allied Market Research has found the global market for regenerative medicine could hit $57 billion by 2023, at a whopping compound annual growth rate of 32 per cent.

“Increased adoption of stem cell technology, emerging application of nanotechnology, rise in prevalence of chronic diseases and trauma emergencies, and advancements in medical equipment technology have boosted growth of the global regenerative medicine market,” it said.

“Increase in potential in emerging economies and growing need of regenerative medicine in organ transplantation are expected to create lucrative opportunities in the near future.”

There are a number of companies listed on the Australian Stock Exchange (ASX) which offer investors exposure to regenerative medicine.

Cynata Therapeutics (ASX:CYP) has experienced very strong share price growth in the past couple of years as it works towards commercialising its “off-the-shelf” stem cell therapy.

Fellow stem cell stock Regeneus (ASX:RGS) is using biomarkers to monitor disease progression in stem cell therapy patients.

This content was produced by Star Investing in commercial partnership with Cynata Therapeutics and Regeneus. This content does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.